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Background. Severe Clostridium difficile infections (CDIs) are associated with a high mortality rate despite medical and/or 
surgical treatment. Fecal microbiota transplantation (FMT) prevents recurrences, but its effect on survival has been shown only 
in patients with O27 ribotype CDI. Here, we investigated whether early FMT could improve survival in hospitalized CDI patients, 
particularly those with severe infection.
Methods. We performed a retrospective cohort study between May 2013 and April 2016 at the infectious diseases department 
of the North University Hospital of Marseille, France. Patients received either medical treatment alone or treatment with early FMT. 
The primary outcome was the 3-month mortality rate.
Results. A total of 111 patients were included: 66 in the FMT group and 45 in the non-FMT group. No patient underwent 
surgery. The O27 ribotype (odds ratio [OR], 3.64 [95% confidence interval {CI}, 1.05– 12.6], P = .04), severe CDI (OR, 9.62 [95% 
CI, 2.16–42.8], P = .003), and FMT (OR, 0.13 [95% CI, .04–.44], P = .001) were independent predictors of 3-month mortality. FMT 
improved survival in severe cases (OR, 0.08 [95% CI, .016–.34], P = .001) but not in nonsevere cases (OR, 1.07 [95% CI, .02–56.3], 
P = .97), independent of age, sex, comorbidities (Charlson score), and ribotype. The number of severe patients who needed to be 
treated to save 1 life at 3 months was 2.
Conclusions. Early FMT dramatically reduces mortality and should be proposed as a first-line treatment for severe CDI. Further 
studies are needed to clarify complications and contraindications. Surgery should be reassessed in this context.
Keywords. Clostridium difficile; fecal microbiota transplantation; mortality; survival; treatment. 
Clostridium difficile infection (CDI) is an emerging worldwide 
public health concern associated with substantial mortality and 
recurrence [1–3]. The mortality rate dramatically increased from 
1.5% before 2000 to 4%–6% and 7%–17% in recent endemic and 
epidemic periods, respectively, in the United States [2]. The mor-
tality rate for severe infection is much higher, reaching 36%–58% 
without surgery and 32%–57% with surgery [4–7], with no signif-
icant difference in the largest meta-analysis to date [8]. Moreover, 
only 30% of patients with severe CDI underwent surgery, in rela-
tion to a selection bias [8]. The emerging epidemic hypervirulent 
O27 ribotype has been associated with high mortality [9] (64% in 
our unit in 2013–2014 [10]). The binary toxin is also considered 
as a virulence factor associated with CDI severity [11]. Other pre-
dictive factors of mortality include age, usual comorbidities, sever-
ity, and specifically, inflammatory bowel disease [12, 13]. Among 
antimicrobial agents to treat CDI, vancomycin was shown to be 
superior to metronidazole, especially for severe colitis [4, 14], but 
resistance is increasing [15]. Fidaxomicin is not superior to vanco-
mycin [16], while rifaximin [17], tolevamer [18] and nitazoxanide 
[19] have been successful as salvage therapy. Other nonmicrobial 
treatments have no demonstrated efficacy [20–22].
Bacteriotherapy, predominantly fecal microbiota transplan-
tation (FMT), has revolutionized the management of patients 
with CDI. The efficacy of FMT on recurrence has been reported 
to range from 70% to 100% in several studies in the literature 
(Supplementary Table 1). The dramatic efficacy of FMT vs van-
comycin was demonstrated on the absence of relapse [23, 24]. 
We first showed that early FMT improved survival in patients 
with CDI caused by the hypervirulent O27 ribotype [10]. In 
severe CDI, the efficacy of FMT in preventing recurrences and 
decreasing the duration of symptoms has been demonstrated, 
though not the efficacy against mortality [25, 26]. Subsequently, 
we successfully treated 2 patients with non-O27 ribotype CDI but 
with severe colitis, including 1 patient in the intensive care unit 
[27]. Based on the continuing ongoing epidemic, the demon-
strated efficacy of FMT in the CDI context, the demonstrated 
biological mechanism (disruption of the gut microbiota during 
CDI restored by FMT) [28, 29], and the relatively good safety and 
long-term tolerance [30–32], we subsequently proposed early 
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FMT to all CDI patients hospitalized in our unit regardless of 
comorbidities, ribotype, recurrence, or severity. Assessments of 
early FMT efficacy are lacking in this context and are of foremost 
importance. Moreover, although the efficacy against recurrence 
has been extensively studied [23, 24] (Supplementary Table 1), 
comparative studies evaluating the role of FMT in improving 
mortality are lacking, especially in non-O27 and nonsevere CDI.
The objective of this study was to compare the mortality of all 
patients hospitalized for CDI in our unit with and without FMT. 
Moreover, as the FMT method changed during the period of 
inclusion (fresh to frozen stool [33]), we compared the efficacy 
of these 2 methods on mortality.
METHODS
Study Population and Center
We performed a 3-year monocentric, retrospective cohort 
study with prospective collection of data following the STROBE 
(Strengthening the Reporting of Observational Studies in 
Epidemiology) guidelines [34] (Supplementary Data 1). The 
study population was all patients hospitalized for colitis with 
C. difficile in the infectious diseases department of the North 
University Hospital of Marseille from May 2013 to April 2016. 
Patient information was extracted from the hospital comput-
erized database DIM (département d’information médicale) 
using the A047 code “pseudomembranous colitis” with col-
itis and/or C. difficile in primary or secondary diagnosis, and 
data were collected using a standardized questionnaire, includ-
ing age, sex, comorbidities (Charlson score [35]), Clostridium 
difficile episodes, and interventions (Supplementary Data 2). 
Patients were followed up at 3, 6, and 12 months. A phone call 
was used to obtain information for those not presenting at con-
trol visits. The exclusion criteria were lack of patient consent, 
age <18 years, and missing data not allowing us to confirm age, 
sex, diagnosis, and treatment. The study was approved by the 
local (Institut Hospitalo-Universitaire Méditerranée Infection) 
ethics committee, number 2017-009. Each patient provided oral 
or written informed consent.
Definitions
CDI was defined as previously reported [13] by the association of 
diarrhea, ileus, or endoscopic colitis associated with microbiologi-
cal evidence (positive polymerase chain reaction with systematic 
research of the O27 ribotype and the binary toxin). Severe colitis 
was defined by leukocytes >15 g/L, albumin <30 g/L, serum cre-
atinine >130 μmol/L or >1.5 times the baseline, peritonitis, occlu-
sive syndrome, megacolon, or signs of shock.
Treatments
The fecal infusion preparation and procedure were previously 
reported [10], except that fresh stools were used from May 
2013 to April 2015, whereas frozen stools (–80°C) were used 
from May 2015 to April 2016. Donors (<65 years of age) were 
relatives or anonymous volunteers selected by a questionnaire 
and microbiological analyses (blood and feces) according to the 
2015 French recommendations of the National Agency for the 
Safety of Medicines (ANSM) [36] (Supplementary Data 3 and 
4). FMT was routinely available with a prespecified protocol 
[10], but the decision to transplant was left to the discretion of 
the clinician in charge of the unit at that time (N. S., C. E., J. K., 
M. D., J. C. L., M. M., or P. B.). Agents and dosages of antimicro-
bial treatment were as follows: for the FMT group: vancomy-
cin 500 mg 4 times daily 2 days before and 4 days after FMT 
for patients with the O27 strain or severe disease (urgent FMT 
protocol), 4 days before and 4 days after for non-O27 strains 
(standard FMT protocol); and the no-FMT group: vancomycin 
orally (500 mg 4 times daily for 10 days), metronidazole orally 
or intravenously (500 mg 3 times daily for 10 days), vancomycin 
associated with metronidazole (same dosages), or fidaxomicin 
orally (200  mg 3 times daily for 10  days) [13], according to 
recurrence, severity, and sensitivity to treatments.
Outcomes
The major outcome was the 3-month all-cause mortality rate. 
As previously reported [37], CDI was deemed the attributable 
cause of death if we judged that the patient would not have 
died within 3 months in the absence of CDI. Death was con-
sidered to be directly related, indirectly related, or unrelated to 
CDI (Supplementary Table 2). The secondary objective was to 
evaluate the tolerance for the various treatments and to com-
pare fresh or frozen FMT, O27 or non-O27 ribotype, and severe 
or nonsevere colitis.
Potential Predictors and Confounding Factors
In addition to FMT, age, sex, Charlson score, O27 ribotype, bin-
ary toxin, hospital/retirement home–acquired CDI, number of 
previous episodes, severe colitis, and mode of FMT preparation 
(fresh or frozen) were tested as independent variables in differ-
ent models.
Statistical Analysis
We compared the 3-month survival rates of patients with or with-
out FMT. Only the first 3 months were considered because most 
(>50%) deaths occurring after 3 months were unrelated to CDI 
(Supplementary Table 2). Student t test or Mann-Whitney test, 
when appropriate, was used to perform 2-group comparisons for 
quantitative variables. The χ2 test or Fisher exact test, when appro-
priate, was used for qualitative variables. Variables with P < .20 in 
the univariate analysis or considered to be clinically important 
were entered into multiple logistic regression models to identify 
independent predictors of 3-month mortality. Preplanned sub-
group analyses included type of preparation (fresh vs frozen), 
ribotype (O27 vs non-O27), severity (severe vs nonsevere) and 
patients treated with vancomycin. To test the robustness of our 
results, including patients lost to follow-up before 3 months, we 
used univariate (Kaplan-Meier curve with log-rank test) and 
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multivariate (Cox model regression) survival analysis. Finally, we 
determined the number needed to treat to save a life (prevent a 
death) at 3 months. A P value <.05 was considered statistically 
significant in all comparisons. The analyses were performed 
using SPSS software version 20.0 (IBM, Paris, France).
RESULTS
Study Population
One hundred thirty patients were screened, and 19 were 
excluded: 14 were ultimately not hospitalized in our department, 
1 had colitis without C. difficile, and 4 had missing data. Overall, 
111 patients were included: 66 had FMT (51 had 1 transplant, 14 
had 2 transplants, and 1 had 3 transplants in cases of relapse with 
good tolerance of the first transplant), 45 patients received medi-
cal treatment alone and no transplant because 4 patients refused, 
1 was no longer symptomatic in our service, 1 had an unex-
pected immunodeficiency and was considered contraindicated, 
and 39 were ultimately rejected according to the physician’s 
discretion (26 were considered to have had good progression 
with antibiotics alone, and 13 were considered too unstable to 
undergo the transplant; these assessments were purely subjec-
tive and physician dependent) (Figure 1). Antimicrobial agents 
included vancomycin (101 patients), metronidazole (26 patients, 
all in the non-FMT group), and fidaxomicin (4 patients, all in 
the no-FMT group). One patient did not receive antimicrobial 
agents in our unit because of spontaneous resolution of diarrhea. 
Dosages followed the local protocols (see Methods).
Our population was older than many published studies 
(median age, 82 years [interquartile range, 72–88 years]; range, 
34–101 years). There were no significant differences in baseline 
characteristics between the 2 groups (Table  1) except for the 
number of recurrences before hospitalization in our unit, which 
was significantly increased in the FMT group (P  =  .02). This 
finding was expected considering the current recommendations.
Study Outcomes
The global mortality rate was 24.3% (27/111) at 3 months after 
the diagnosis of CDI: 12.1% (8/66) in the transplant group vs 
42.2% (19/45) in the antibiotic group (univariate odds ratio 
[OR], 0.19 [95% confidence interval {CI}, .073–.49], P < .0003). 
No patient underwent colectomy. Antimicrobial agents could 
not be compared, as all patients in the FMT group received 
vancomycin and none received either metronidazole or fidax-
omicin. Consequently, vancomycin and FMT were perfect pre-
dictors and could not be included together in our models. In 
the FMT group, there were 6 (2 direct and 4 indirect) deaths 
related to CDI and 2 deaths unrelated to CDI. In the no-FMT 
group, there were 15 (12 direct and 3 indirect) deaths related 
to CDI and 4 unrelated deaths (Supplementary Table 2). There 
was only 1 death among patients <65 years of age (0/66 in the 
FMT group and 1/45 [2.2%] in the no-FMT group). Most of 
the deaths occurred in patients between 81 and 90  years of 
age (Supplementary Figure 1). Six (5.4%) patients were lost to Figure 1. Study flowchart.
Table 1. Baseline Patient Characteristics
Characteristic
FMT
(n = 66)
No FMT
(n = 45) P Value
Age, y, median (IQR) 81 (69–87) 83 (72–88) .84a
Age >65 y 60 (91) 36 (80) .10b
Age >80 y 36 (54) 26 (58) .74b
Male sex 23 (35) 13 (29) .51b
Charlson comorbidity index, 
median (range)c
2 (1–3) 2 (1–4) .17a
WHO performance status, 
median (range)d
3 (1–3) 2 (2–3) .20a
Patients with dementia 15 (23) 12 (27) .63b
Bedridden patients 27 (41) 18 (40) .92b
Use of proton pump inhibitor 30 (45) 22 (49) .72b
Recent admission to a hospitale 54 (82) 35 (78) .60b
Antibiotic use before CDIf 57 (87) 38 (84) .78b
Hospital/retirement home- 
acquired CDI
44 (67) 28 (62) .63b
Binary toxin 34 (51) 27 (60) .37b
Ribotype O27 28 (42) 25 (56) .17b
Median recurrences, No. (range) 0 (0–5) 0 (0–3) .02 a
Severe colitis 37 (56) 27 (60) .68b
Leukocyte count, median (IQR) 11.1 (7.4–18.4) 13.7 (7.6–18.7) .59a
Leukocyte count >15 000  
cells/mL
25 (38) 18 (40) .82b
Albumin, g/L, median (IQR) 31.3 (25.7–35.2) 31.6 (24.6–34.7) .49a
Albumin <30 g/L 31 (47) 20 (44) .79b
Serum creatinine, median (IQR) 91.8 (64.0–161.5) 79.9 (59.2–132.6) .22a
Serum creatinine >133 µmol/L or 
>1.5 times the premorbid level
16 (24) 13 (29) .58b
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CDI, Clostridium difficile infection; FMT, fecal microbiota transplantation; 
IQR, interquartile range; WHO, World Health Organization.
aTwo-sided Mann-Whitney test.
bTwo-sided χ2 test.
cCharlson score: index of comorbidities corresponding to the 1-year mortality risk. 
dWHO performance status: patient autonomy indicator from 0 to 4. 
eMore than 2 days in the previous 3 months. 
fIn the 3 months preceding.
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follow-up before 3 months (5 in the FMT group [25, 35, 49, 52, 
and 67 days] and 1 in the no-FMT group [29 days]).
Hospital/retirement home-acquired CDI, the number of pre-
vious episodes, and the binary toxin were not associated with 
3-month mortality in any of these models (Supplementary 
Tables 3–5). Accordingly, all final multivariable models included 
age, sex, Charlson score, O27 ribotype, severe colitis, and FMT. 
Age (OR, 1.07 [95% CI, 1.002–1.14], P = .045), Charlson index 
(OR, 1.46 [95% CI, 1.07–1.99], P = .02), the O27 ribotype (OR, 
3.64 [95% CI, 1.05–12.6], P =  .04), severe CDI (OR, 9.6 [2.2–
42.8], P = .003), and FMT (OR, 0.13 [95% CI, .04–.44], P = .001) 
were independent predictors of 3-month mortality. The number 
of patients who needed to be treated to save 1 life at 3 months 
was 4 (95% CI, 2.2–7.5).
Subgroup Analyses
Thirty (45.5%) transplants were performed using fresh stools 
and 36 (54.5%) with frozen stools. Among patients with FMT, 
no significant difference was found between frozen and fresh 
FMT (logistic regression: OR, 2.8 [95% CI, .44–18.0], P = .28,). 
FMT decreased mortality regardless of the O27 ribotype (O27 
positive: OR, 0.14 [95% CI, .03–.61], P  =  .009; O27 negative: 
OR, 0.072 [95% CI, .005–1.10], P  =  .059). In contrast, FMT 
decreased mortality only in patients with severe colitis. A total 
of 6 of 34 (17%) patients died in the FMT group vs 18 of 26 
(69%) in the non-FMT group (bilateral χ2 test, P <  .0001). In 
this group, the number of patients who needed to be treated to 
save 1 life at 3 months was 2 (95% CI, 1.4–3.4). This finding was 
confirmed in the multivariate analyses (severe CDI: OR, 0.075 
[95% CI, .016–.34], P = .001; nonsevere CDI: OR, 1.07 [95% CI, 
.02–56.3], P = .97).
Because vancomycin could have been responsible for the 
observed improved prognosis because it was administered in 66 
of 66 (100%) patients in the FMT group according to local pro-
tocols (see Methods) but in only 35 of 45 (78%) in the no-FMT 
group (Fisher exact test, P < .0001), we performed a subgroup 
analysis of the 101 patients treated with vancomycin (only 10 
included patients did not receive vancomycin). FMT remained 
associated with a similar improved survival (OR, 0.08 [95% 
CI, .02–.32], P = .0003), confirming that the choice of the anti-
microbial agent was not responsible for the observed effect.
Survival Analysis
To test the robustness of our results, including the 6 patients lost 
to follow-up before 3 months, we performed a survival analysis; 
FMT was associated with a very significant decrease in mortal-
ity (log-rank test, P <   .0002; Supplementary Figure 2), which 
was confirmed in a Cox regression model (hazard ratio [HR], 
0.23 [95% CI, .095–.541], P =  .001; Supplementary Figure 3). 
FMT reduced mortality only in patients with severe CDI (log-
rank test, P <  .0001; Figure 2A) but not those with nonsevere 
CDI (P  <  .86; Figure  2B), and this finding was confirmed in 
the multivariate analyses (severe CDI: HR, 0.15 [95% CI, .06–
.39], P <  .0001; nonsevere CDI: HR, 0.61 [95% CI, .02–20.5], 
P = .78), consistent with the logistic regression analyses.
DISCUSSION
Here, we showed that early FMT dramatically prevented mor-
tality in patients with severe CDI. Risk of bias was low because 
baseline characteristics were similar and multivariate survival 
models were used. Antimicrobial agents are unlikely to play a 
confounding role, as effect size was unchanged, selecting only 
Figure 2. Effects of fecal microbiota transplantation (FMT) on Clostridium difficile infection (CDI) survival according to severity. Green line: FMT. Blue line: No FMT. A, Early 
FMT dramatically reduced mortality in patients with severe CDI (Kaplan-Meier curve, log-rank test, P < .0001). B, Early FMT did not reduce mortality in patients with nonsevere 
CDI (Kaplan-Meier curve, log-rank test, P = .86).
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patients treated with vancomycin. In our study, FMT by naso-
gastric tube was well tolerated, with no serious adverse effects. 
In a recent systematic review [30], the death rate attributed to 
FMT was evaluated to be 3 of 1190 (0.25%), which seems very 
low compared with CDI-attributable mortality in patients with 
severe infection without FMT (69% in this study). Adverse 
events mainly included mild gastrointestinal symptoms and 
fever. Severe complications included infections, autoimmune 
complications, and exacerbation of inflammatory bowel disease.
According to some authors, double-blind, randomized, mul-
ticenter trials should be performed in different countries before 
modifying the recommendations for first-line treatment of 
patients with severe CDI. However, clinical judgment should 
always guide methodology and statistical analysis [38]. In fatal 
emerging infections, such as human immunodeficiency virus in 
1990 [39], Ebola in 2015 [40], and currently C. difficile, the use 
of nonrandomized trials was justified only when 5 conditions 
were met: (1) patients who do not receive treatment have a uni-
formly unfavorable prognosis; (2) the treatment should not be 
associated with serious and substantial side effects; (3) the poten-
tial benefit is sufficiently high to merit a trial; (4) the scientific 
rationale must be strong enough for a positive result to be gener-
ally accepted; and (5) there should be no other appropriate treat-
ment for use as a control. Moreover, according to the Grading 
of Recommendations Assessment, Development and Evaluation 
(GRADE) working group [41], beyond the quality of evidence, 
the judgment on the strength of a recommendation requires 
considering the following elements in addition to those already 
mentioned: (6) “directness,” which is the fact that the population, 
intervention, and measurement of the outcome in the study are 
similar to those of interest under real circumstances; (7) the rela-
tive importance of the outcome (critical or noncritical, surrogate); 
(8) the risk-benefit ratio; and (9) the cost (the use of resources).
Regarding our study, (1) patients with severe CDI without 
FMT had a very severe prognosis with very high mortality 
(30%–60%); (2) FMT has a good safety profile compared with 
CDI and surgery; (3) the potential benefit was sufficiently high 
(OR,  <0.2 [41]) to be unambiguous; (4) the scientific ration-
ale, including all available clinical studies taking recurrence as 
outcome and basic research studies on microbiota restoration, 
was sufficiently strong for the result to be generally accepted; 
(5) surgery, usually proposed as salvage therapy in severe cases, 
was not an appropriate treatment to serve as a control because 
it could be proposed only in selected patients (30%), the benefit 
was not demonstrated, mortality remained very high in oper-
ated patients (32%–57%) [4–8], and the quality of life in survi-
vors is strongly altered; (6) directness seemed optimal, as our 
study, conducted in the epicenter and period of a C. difficile epi-
demic [9], included a population that would benefit the most 
from first-line FMT, including the oldest (mean age, 82 years), 
the most sick (severe patients were not excluded, in contrast to 
many published studies), and those with the most comorbidities 
(based on a high Charlson score and high prevalence rates of 
bedridden and dementia in our population); (7) the outcome 
was critical (mortality from any cause) and not questionable 
(no surrogate); (8) the risk-benefit ratio was high; and (9) the 
cost (use of resources) for society was quite reasonable as the 
procedure was already routinely performed in the frequent 
indications currently accepted (recurrence). Modification of 
the recommendations would therefore result in negligible add-
itional costs for healthcare systems.
Therefore, waiting for double-blind randomized controlled 
trials to update the recommendations and management of the 
most vulnerable and severely ill C.  difficile–infected patients 
who are at very high risk of mortality (one of the highest risks 
among infectious diseases, higher than the 2014–2015 Ebola 
virus fatality rate (39%; www.who.int) does not seem eth-
ical. This issue illustrates the “parachute paradigm” [42, 43]. 
Alternatively, we advocate confirming this benefit in nonrand-
omized studies, taking as controls those who refuse treatment 
(in our experience, a very small minority of patients with severe 
disease, in view of the suffering and anxiety associated with 
severe CDI) or with controlled before-and-after studies.
Additional studies are needed to clarify the short- and long-
term complications and the few contraindications of FMT via 
any route (colonic FMT could be used in patients with ileus or 
occlusive syndrome). In such patients, medical treatment alone 
or surgery (perforation, peritonitis) would remain the only sal-
vage treatments, though these therapies are associated with very 
poor prognoses. Overall, as suggested by Brandt et al [44], our 
results strongly suggest that early FMT should be proposed as a 
“first-line” treatment for severe CDI.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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